Eli Lilly & Co. received approval from the U.S. Food and Drug Administration Feb. 2 for a drug developed with Boehringer Ingelheim Pharmaceuticals Inc. to better manage blood sugar in type 2 diabetes patients.
Read more here.
According to an Oct. 14, 2014 article in The Wall Street Journal (WSJ), Eli Lilly is “on the mend.” Why? “The company has received regulatory approval to sell three new drugs—two for diabetes and one for gastric cancer—and has more experimental drugs in late-stage clinical testing.”
Eli Lilly Chief Executive John C. Lechleiter told the WSJ in this article that 2014 was the “toughest year” in the drug maker’s 138-year history because of generic competition following patent expirations for several of its top-selling drugs.
Here’s to a great 2015!